Visceral leishmaniasis in the BALB/c mouse: A comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2722-2725

  Mullen, A B ^a   Baillie, A J ^a   Carter, K C ^a,b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b Department of Immunology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; STIBOGLUCONATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG FORMULATION; HUMAN; INJECTION SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; VISCERAL LEISHMANIASIS;

EID: 0031658033     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2722     Document Type: Article

References (12)

1. Baillie, A. J., T. F. Dolan, J. Alexander, and K. C. Carter. 1989. Visceral leishmaniasis in the BALB/c mouse: sodium stihogluconate treatment during acute and chronic stages of infection. Int. J. Pharm. 57:23-28.
2. Banduwardene, R., A. Mullen, and K. C. Carter. 1997. Immune responses of L. donovani infected BALB/c mice following treatment with free and vesicular sodium stibogluconate. Int. J. Immunopharmacol. 19:195-203.
3. Berman, J. D. 1997. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24:684-703.
4. Bradley, D. J., and J. Kirkley. 1977. Regulation of Leishmania populations within the host. I. The variable course of Leishmania donovani infections in mice. Clin. Exp. Immunol. 30:119-129.
5. Carter, K. C., A. J. Baillie, J. Alexander, and T. F. Dolan. 1988. The therapeutic effect of sodium stihogluconate in BALB/c mice infected with Leishmania donovani is organ dependent. J. Pharm. Pharmacol. 40:370-373
6. Carter, K. C., T. F. Dolan, J. Alexander, A. J. Baillie, and C. McColgan. 1989. Visceral leishmaniasis: drug carrier system characteristics and the ability to clear parasites from the liver, spleen and bone marrow in Leishmania donovani infected BALB/c mice. J. Pharm. Pharmacol. 41:87-91.
7. Clemons, K. V., and D. A. Stevens. 1998. Comparison of Fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis. Antimicrob. Agents Chemother. 42:899-902.
8. Gangneux, J.-P., A. Sulahian, Y. J.-F. Garin, and F. Derouin. 1996. Lipid formulations of amphotericin B in the treatment of experimental visceral leishmaniasis due to Leishmania infantum. Trans. R. Soc. Trop. Med. Hyg. 90:574-577.
9. Gangneux, J.-P., A. Sulahian, Y. J.-F. Garin, R. Farinotti, and F. Derouin. 1996. Therapy of visceral leishmanisis due to Leishmania infantum: experimental assessment of efficacy of AmBisome. Antimicrob. Agents Chemother. 40:1214-1218.
10. Mullen, A. B., K. C. Carter, and A. J. Baillie. 1997. Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis. Antimicrob. Agents Chemother. 41:2089-2092.
11. Seaman, J., D. Pryce, H. E. Sondorp, A. Moody, A. D. M. Bryceson, and R. N. Davidson. 1993. Epidemic visceral leishmaniasis in Sudan: a randomised trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. 168:715-720.
12. Williams, D. M., K. C. Carter, and A. J. Baillie. 1995. Visceral leishmaniasis in the BALB/c mouse: a comparison of the in vivo activity of five non-ionic surfactant vesicle preparations of sodium stibogluconate. J. Drug Target. 3: 1-7.